Hellwig Dirk, Samnick Samuel, Reif Johannes, Romeike Bernd F M, Reith Wolfgang, Moringlane Jean R, Kirsch Carl-Martin
Department of Nuclear Medicine, Saarland University Medical School, Homburg-Saar, Germany.
Clin Nucl Med. 2002 Nov;27(11):781-4. doi: 10.1097/00003072-200211000-00005.
For more than a decade, In-111 octreotide has been known to accumulate in meningiomas as a result of the expression of subtype 2 somatostatin receptors. Improved imaging characteristics can be expected with the recently developed radiotracer Tc-99m depreotide, which also binds to subtype 2 somatostatin receptors.
The authors examined a patient with intraorbital and extracranial recurrent meningioma using SPECT with Tc-99m depreotide and In-111 octreotide. The tumor-to-background ratios in the lesions were compared and the findings were correlated with histopathologic findings.
Although the tumor-to-background ratios were higher for the In-111-labeled tracer in the largest tumor lesion (5.7 versus 3.3), SPECT with the Tc-99m-labeled compound showed a proved second site of recurrence as a result of the better resolution that can be achieved with that isotope. CONCLUSIONS SPECT: with Tc-99m depreotide appears to be clinically useful for detecting recurrent meningiomas with higher resolution and may outperform In-111 octreotide imaging in patients with meningiomas.
十多年来，由于2型生长抑素受体的表达，铟-111奥曲肽一直被认为会在脑膜瘤中蓄积。最近开发的放射性示踪剂锝-99m地普肽也与2型生长抑素受体结合，预计其成像特性会有所改善。
作者使用锝-99m地普肽和铟-111奥曲肽对一名患有眶内及颅外复发性脑膜瘤的患者进行了单光子发射计算机断层扫描（SPECT）检查。比较了病变中的肿瘤与本底比值，并将结果与组织病理学结果相关联。
尽管在最大的肿瘤病变中，铟-111标记的示踪剂的肿瘤与本底比值更高（5.7比3.3），但使用锝-99m标记化合物的SPECT显示出一个已证实的复发第二部位，这是由于该同位素能够实现更好的分辨率。结论：锝-99m地普肽SPECT在检测复发性脑膜瘤方面似乎具有临床实用性，分辨率更高，在脑膜瘤患者中可能优于铟-111奥曲肽成像。
